Transcranial attenuation (TA) of bone-conducted sound has a high degree of variability by frequency and subject, which may play a role in the objective benefit of individuals with single-sided deafness (SSD) treated with a bone-anchored implant (BAI). This study sought to determine whether TA is predictive of benefit in individuals with SSD who receive a BAI. Adult, English-speaking patients with unilateral profound sensorineural hearing loss who underwent a BAI evaluation were included for study. Absolute TA values were consistent with previously published reports. Regression analysis indicated no correlation between TA values and aided speech-in-noise performance for any combined or individual frequencies. Measures of TA do not provide predictive value in determining behavioral outcomes in the SSD population. Specifically, low TA does not suggest improved outcomes with a BAI.

Keywords:
Transcranial attenuation, Single-sided deafness, Bone-anchored hearing aid, Bone-anchored implant, Speech-in-noise
1.
Andersen HT, Schroder SA, Bonding P: Unilateral deafness after acoustic neuroma surgery: subjective hearing handicap and the effect of the bone-anchored hearing aid. Otol Neurotol 2006;27:809-814.
2.
Bosman AJ, Hol MK, Snik AF, Mylanus EA, Cremers CW: Bone-anchored hearing aids in unilateral inner ear deafness. Acta Otolaryngol 2003;123:258-260.
3.
Carhart R, Jerger J: Preferred methods for clinical determination of pure-tone thresholds. J Speech Hear Res 1959;24:330-345.
4.
Faber HT, de Wolf MJF, Cremers CWRJ, Snik AFM, Hol MKS: Benefit of BAHA in the elderly with single-sided deafness. Eur Arch Otorhinolaryngol 2013;270:1285-1291.
5.
FDA: Summary and Certification. 510(k) Summary No K021837. Rockville, FDA, 2002.
6.
Giolas TG, Wark DJ: Communication problems associated with unilateral hearing loss. J Speech Hear Disord 1967;32:336-343.
7.
Hakansson B, Tjellstrom A, Rosenhall U: Hearing thresholds with direct bone conduction versus conventional bone conduction. Scand Audiol 1984;13:3-13.
8.
Hol MK, Bosman AJ, Snik AF, Mylanus EA, Cremers CW: Bone-anchored hearing aid in unilateral inner ear deafness: a study of 20 patients. Audiol Neurootol 2004;9:274-281.
9.
Hood JD: The principles and practice of bone conduction audiometry: a review of the present position. Laryngoscope 1960;70:1211-1228.
10.
Kompis M, Pfiffner F, Krebs M, Caversaccio MD: Factors influencing the decision for BAHA in unilateral deafness: the Bern benefit in single-sided deafness questionnaire. Adv Otorhinolaryngol 2011;71:103-111.
11.
Lin LM, Bowditch S, Anderson MJ, May B, Cox KM, Niparko JK: Amplification in the rehabilitation of unilateral deafness: speech in noise and directional hearing effects with bone-anchored hearing and contralateral routing of signal amplification. Otol Neurotol 2006;27:172-182.
12.
Mylanus EA: Influence of the thickness of the skin and subcutaneous tissue covering the mastoid on bone-conduction thresholds obtained transcutaneously versus percutaneously. Scand Audiol 1994;23:201-203.
13.
Niparko JK, Cox KM, Lustig LR: Comparison of the bone anchored hearing aid implantable hearing device with contralateral routing of offside signal amplification in the rehabilitation of unilateral deafness. Otol Neurotol 2003;24:73-78.
14.
Nolan M, Lyon DJ: Transcranial attenuation in bone conduction audiometry. J Laryngol Otol 1981;95:597-608.
15.
Research E: Quick Speech-in-Noise Test. Elk Grove Village, Etymotic Research, 2001.
16.
Sargent EW, Herrmann B, Hollenbeak CS, Bankaitis AE: The minimum speech test battery in profound unilateral hearing loss. Otol Neurotol 2001;22:480-486.
17.
Snapp HA, Angeli SI, Telischi FF, Fabry DA: Postoperative validation of bone-anchored implants in the single-sided deafness population. Otol Neurotol 2012;33:291-296.
18.
Snapp HA, Fabry DA, Telischi FF, Arheart KL, Angeli SI: A clinical protocol for predicting outcomes with an implantable prosthetic device (BAHA) in patients with single-sided deafness. J Am Acad Audiol 2010;21:654-662.
19.
Snik AF, Bosman AJ, Mylanus EA, Cremers CW: Candidacy for the bone-anchored hearing aid. Audiol Neurootol 2004;9:190-196.
20.
Snyder JM: Interaural attenuation characteristics in audiometry. Laryngoscope 1973;83:1847-1855.
21.
Stenfelt S: Bilateral fitting of BAHAS and BAHA fitted in unilateral deaf patients: acoustical aspects. Int J Audiol 2005;44:78-189.
22.
Stenfelt S: Transcranial attenuation of bone-conducted sound when stimulation is at the mastoid and at the bone conduction hearing aid position. Otol Neurotol 2012;33:105-114.
23.
Stenfelt S, Goode RL: Bone-conducted sound: physiological and clinical aspects. Otol Neurotol 2005;26:1245-1261.
24.
Taylor B: Speech-in-noise tests: how and why to include them in your basic test battery. Hear J 2003;56:40, 42-46.
25.
Tillman TW, Carhart R: An expanded test for speech discrimination utilizing CNC monosyllabic words; in Chaiklin JB, Ventry IM, Dixon RF (eds): Northwestern University Auditory Test No. 6 Hearing Measurement: A Book of Readings. Reading, Addison-Wesley, 1966, pp 226-235.
26.
Wazen JJ, Ghossaini SN, Spitzer JB, Kuller M: Localization by unilateral BAHA users. Otolaryngol Head Neck Surg 2005;132:928-932.
27.
Wazen JJ, Spitzer JB, Ghossaini SN, Fayad JN, Niparko JK, Cox K, Brackmann DE, Soli SD: Transcranial contralateral cochlear stimulation in unilateral deafness. Otolaryngol Head Neck Surg 2003;129:248-254.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.